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Introduction 
A wide variety of dermatologic adverse effects are 
known complications of immunotherapy. We report 
a novel case of the onset of pili multigemini 
following systemic treatment with dabrafenib and 
trametinib in a patient with stage IV melanoma. 
 
Case Synopsis 
A 52-year-old man with a history of stage IV 
metastatic melanoma presented to the dermatology 
clinic for a routine full-body examination. He had 
diffuse metastatic disease with abdominal 
carcinomatosis, pulmonary nodules, and 
leptomeningeal and central nervous system 
involvement and was on a systemic chemotherapy 
regimen of dabrafenib and trametinib. While on 
immunotherapy the patient experienced a transient 
alopecia which self-resolved and upon regrowth of 
the hair he noticed a dark patch of hair on the 
occipital scalp. The patient denied any hair or scalp 
discoloration issues prior to the start of the regimen. 
On physical examination, there was a 45×35mm 
well-circumscribed area on the posterior scalp 
(Figure 1). Dermoscopy showed multiple hair shafts 
derived from the same follicular units resulting in an 
apparent darkening of the hair and scalp related to 
increased hair density with no darkening or 
hyperpigmentation of the scalp itself (Figure 2). The 
patient reported no issues with this irregular hair 
growth and was continued on his regimen without 
alteration. 
Abstract 
The combination of dabrafenib and trametinib is an 
important immunotherapy option for patients with 
BRAF V600 mutation-positive melanoma. This 
regimen has been reported to cause cutaneous 
eruptions. However, hair dysmorphology is not a 
reported side effect to these or any other 
medications to date. Herein, we highlight a case of 
pili multigemini formation in a patient with stage IV 
melanoma receiving treatment with dabrafenib and 
trametinib and the corresponding clinical findings. 
 
Figure 1. Gross appearance of a well-circumscribed area on the 
occipital scalp with new multigeminate hair formation.
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Case Discussion 
Pili multigemini is a hair malformation characterized 
by the presence of multiple hair shafts with distinct 
cuticles originating from a single pilosebaceous 
canal. The multigeminate hairs, enclosed by a 
common bulb, emerge from a single follicular ostium 
[1]. It is often a finding in male beards, but has been 
reported in women, children, and in all body hair 
types [2]. In general, pili multigemini is a benign 
asymptomatic condition that does not require 
removal. Some patients elect for removal owing to 
cosmetic concerns, with electrolysis being the most 
common method; there have been reports of 
depilating laser treatment for symptomatic cases [3]. 
Other hair shaft abnormalities with multiple hairs  
emerging from a single follicle include tufted hair 
folliculitis, that often follows scarring alopecia, and 
compound follicles, which can be a normal finding 
[4]. 
Combination immunotherapy with dabrafenib, a 
BRAF inhibitor, and trametinib, a MEK inhibitor, is a 
current treatment for BRAF V600 mutation-positive 
melanoma and significantly improves survival in 
metastatic disease [5]. Adverse events associated  
with the dabrafenib and trametinib combination 
include pyrexia, chills, fatigue, rash, and nausea. 
Cutaneous adverse events during treatment is well 
established [5]. In a multivariate analysis of 
randomized clinical trials with dabrafenib and 
trametinib, the most common side effects were 
cutaneous changes. Cutaneous eruption was the 
most common, with hyperkeratosis, 
photosensitivity, hair growth modification, alopecia, 
cutaneous squamous cell carcinoma, and new 
primary melanoma also reported [6]. Alopecia is a 
known side effect of this combination therapy. 
However, hair shaft dysplasia has not been reported. 
Focal hair pigmentation has been reported following 
immunotherapy, most commonly anti-programmed 
cell death 1 and anti-programmed cell death ligand 
1 agents [7]. Although the exact mechanism is 
unknown, the etiology is likely multifactorial, with 
possible genetic linkage or the reactivation of silent 
embryonic epithelial germ cells producing the 
dysplastic follicle [1]. BRAF is a proto-oncogene that 
regulates the MAP kinase/ERK signaling pathways. 
This pathway is integral to cell division and 
differentiation. Our patient’s acquired pili 
multigemini may support the hypothesis that these 
dysplastic follicles develop after reactivation of germ 
cell genes. Until now, pili multigemini has neither 
been reported as a possible side effect of the 
combination of dabrafenib and trametinib nor other 
systemic cancer therapies. 
 
Conclusion 
Although there are no known adverse effects 
associated with pili multigemini, aside from cosmetic 
considerations, it is important to recognize that it 
may be caused by a common combination 
immunotherapy regimen for melanoma to avoid 
potential patient harm and unnecessary workup. 
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Figure 2. Dermoscopy showing multiple hair shafts emerging 
from single follicular units. The arrow indicates an example of pili 
multigemini and an arrowhead to show uninvolved hair follicles. 
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